Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: A report of three cases

Respiratory Medicine

Volumn 102, Issue 2, 2008, Pages 273-279

  Wilcox, Brad E ^a   Ryu, Jay H ^a   Kalra, Sanjay ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Colorectal cancer; FOLFOX; Interstitial lung disease; Oxaliplatin; Pulmonary fibrosis

Indexed keywords

METHYLPREDNISOLONE; OXALIPLATIN;

ADULT; AGED; ANAMNESIS; ARTICLE; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LUNG DISEASE; LUNG FUNCTION TEST; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY FAILURE;

AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; ORGANOPLATINUM COMPOUNDS; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 37349125978     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.09.001     Document Type: Article

References (17)

1. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
2. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
3. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
4. Rothenburgh M.L., Orza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil plus leucovorin: interim results of a phase III trial. J Clin Oncol 21 (2003) 2059-2069
5. Ramanathan R.K., Clark J.W., Kemeny N.E., et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 15 (2003) 2904-2911
6. Pasetto L.M., and Monfardini S. Is acute dyspnea related to oxaliplatin administration?. World J Gastroenterol 12 (2006) 5907-5908
7. Jung K.H., Kil S.Y., Choi I.K., et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-flurouracil and leucovorin (FOLFOX). Int J Tuberc Lung Dis 10 (2006) 1181-1182
8. Yague X.H., Soy E., Merino B.Q., et al. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 11 (2005) 515-517
9. Trisolini R., Lazzari Agli L., Tassinari D., et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 18 (2001) 243-245
10. Gagnadoux F., Roiron C., Carrie E., Monnier-Cholley L., and Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 25 (2002) 338-390
11. Brandi G., Pantaleo M.A., Galli C., et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89 (2003) 477-481
12. Churg A., and Muller N.L. Cellular vs fibrosing interstitial pneumonias and prognosis: a practical classification of the idiopathic interstitial pneumonias and pathologically/radiologically similar conditions. Chest 130 (2006) 1566-1570
13. Hunninghake G.W., Lynch D.A., Galvin J.R., et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 124 (2006) 1215-1223
14. Rubbia-Brandt L., Audard V., Sartoretti P., Roth A.D., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
15. Kinnula V.L., Vuorinen K., Ilumets H., et al. Thiol proteins, redox modulation and parenchymal lung disease. Curr Med Chem 14 (2007) 213-222
16. Dimopoulou I., Efstathiou E., Samakovli A., et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15 (2004) 1250-1255
17. Dimopoulou I., Galani H., Dafni U., et al. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 94 2 (2002) 452-458